Otros idiomas Nxera Pharma Co., Ltd.

Acciones

4565

JP3431300007

Diferido Japan Exchange Otros sitios de cotización 08:00:00 18/06/2024			Varia. Cinco días.	Varia. 1 de enero.
1.519 ^JPY	-0,85 %		-1,68 %	+6,90 %

30/05	Nxera Pharma recibirá 4,6 millones de dólares en pagos por hitos de Centessa Pharmaceuticals	CI
30/05	Nxera Pharma Co., Ltd. y PrecisionLife amplian su asociacion estrategica de I+D a una nueva area terapeutica	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals	31/05
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	30/05
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area	30/05
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals	30/05
Nxera Pharma Co., Ltd. and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area	30/05
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	10/05
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults	09/05
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024	09/05
Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	18/04
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan	17/04
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	17/04
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16/04
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16/04
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	16/04
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea	15/04
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	15/04
Nxera Pharma joins the World Orphan Drug Alliance	08/04
Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC	03/04
Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC	03/04
Sosei Group Corporation will Change its Name to Nxera Pharma Co., Ltd	01/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Nxera Pharma Co., Ltd.

Acciones

4565

JP3431300007

Otros idiomas

Filtros